[MET] MetLife: Q3 2026 Earnings Test Group Life Mortality, Retirement Spreads and VII

MetLife is an insurance and asset-management group whose three main profit engines are U.S. Group Benefits, Retirement and Income Solutions (RIS) and Asian life insurance, and the company has announced that it will release results for the third quarter of 2026 (2026年第三季度(截至2026年9月30日的三个月), the three months ended September 30, 2026) after the U.S. market close on November 4, 2026, with its earnings call on 2026-11-05[1]. In the latest disclosed quarter, the second quarter of 2026, premiums, fees and other revenues rose 7% year over year to $13.652 billion, net investment income rose 18% to $6.702 billion, net income was $705 million, adjusted earnings per share rose 20% to $2.43, and adjusted ROE was 17.0%[2]. The company does not give quarterly earnings guidance, but its 2025 annual report kept the near-term annual targets of double-digit growth in adjusted EPS excluding notable items and an adjusted ROE of 15%-17%[3]. The Drillr-compiled consensus of 12 analysts for third-quarter EPS is $2.77 (range $2.66-$2.91), and the revenue consensus from 5 analysts is $19.855 billion, although that revenue figure is not defined the same way as the company's premiums, fees and other revenues[4]; $2.77 is about 17% above the $2.37 reported a year earlier[5].

Three things matter most in the third-quarter report. The first is group life mortality: the second-quarter mortality ratio fell to 79.0%, below the company's full-year target range of 83%-88%[6], and management said about 2 percentage points came from prior-period adjustments and lower claim amounts, with July data already starting to normalize[7], so whether the ratio stays below 82% in the third quarter determines how much of Group Benefits' $503 million quarterly profit can last. The second is the RIS core spread and liability growth: the core spread excluding variable investment income (VII) recovered to 1.00% in the second quarter[8], yet segment earnings grew only 2% to $377 million[9], and the second half needs roughly $386 million a quarter to hold the bottom of the $1.6-$1.8 billion full-year guidance[10]. The third is whether VII and buybacks together can carry per-share earnings: company-wide after-tax VII fell from $409 million in the first quarter to $183 million in the second[11][12], while shares outstanding fell from 666.8 million to 637.8 million over a year[13], and if VII does not recover, underwriting and a lower share count alone will struggle to lift EPS to the level the market is looking for.

Company Background and Business Structure

MetLife is a group that runs life insurance, annuities, employee benefits and asset management across the U.S., Asia, Latin America and Europe, the Middle East and Africa, and after a 2025 segment reorganization it reports six segments, Group Benefits, RIS, Asia, Latin America, EMEA and MetLife Investment Management (MIM), plus Corporate & Other[14]. Corporate & Other holds the run-off businesses from the former MetLife Holdings segment that the company no longer actively markets in the U.S., including variable, universal and term life, whole life, fixed and variable annuities, and long-term care insurance[15]. According to the 2025 annual report, adjusted earnings were $1.692 billion for Group Benefits, $1.671 billion for RIS, $1.702 billion for Asia, $798 million for Latin America, $367 million for EMEA and $200 million for MIM, so the top three segments made up about 79% of the six-segment total[16].

Group Benefits is the largest segment by revenue, with about $26.88 billion of segment revenue in 2025, or about 37% of the six segments combined[16]. It sells group life, dental, short- and long-term disability, paid family and medical leave, accident and health, vision, prepaid legal plans and pet insurance to U.S. employers and their employees, and offers administrative-services-only arrangements to some employers; its sales force is organized by customer size and sells directly or through brokers and consultants, while employers have been placing more weight on voluntary, employee-paid products[17].

RIS and Asia are the other two profit pillars, and both earn money on the invested assets behind long-dated liabilities. RIS takes on long-dated liabilities such as pension risk transfers (PRT), structured settlements, U.K. longevity reinsurance and U.K. funded reinsurance[18], and it issues funding agreements to raise institutional money[19]. Asia centers on Japan, which sells foreign-currency annuities, yen life insurance and medical cover, while Korea is driven mainly by life premium growth[20]. Latin America's growth comes mainly from Brazil, Mexico and Chile, EMEA and MIM earn less, and MIM had about $748 billion of total assets under management at the end of June 2026[7].

Over the past year the company has used an acquisition, reinsurance and a sale to reshape its portfolio toward lower capital use and a larger asset-management business. On December 30, 2025, it completed the acquisition of global asset manager PineBridge Investments for preliminary cash consideration of $885 million at closing and folded it into MIM to expand institutional asset management[21]. Also in 2025, it signed two funds-withheld reinsurance agreements with Chariot Re, ceding certain structured settlement annuities, PRT group annuities and participating whole life business[22]; in the first quarter of 2026 it also divested its business in Ukraine[10].

Insurance cash flow comes in first and goes out later, so profit is released gradually over the life of the liabilities. Group policies renew annually and pay claims within the year, while RIS and Asian savings products collect large premiums or deposits up front and invest them in fixed-income securities, commercial mortgage loans, real estate and private funds; in the second quarter, fixed maturity securities and mortgage loans contributed $4.094 billion and $1.097 billion of investment income[23]. Because PRT premiums are booked together with the matching benefit reserves, swings in RIS revenue do not translate directly into profit[18].

Financial History and Current Position

The annual record shows steadily rising revenue but net income that swings sharply with investment and derivative results. According to Drillr-compiled financial data, total revenue rose from $63.366 billion in 2021 to $67.709 billion in 2023 and $77.084 billion in 2025, while net income in those years was $6.855 billion, $1.578 billion and $3.379 billion. Adjusted earnings, the measure the company prefers, strip out those gains and losses, and the six segments' adjusted earnings totaled about $6.43 billion in 2025[16]. Holding-company liquid assets were $3.6 billion at the end of 2025, down from $5.1 billion a year earlier[24].

Operating results in the second quarter of 2026 were clearly stronger than a year earlier, but the gap between reported and adjusted earnings remained large. Premiums, fees and other revenues were $13.652 billion, net investment income was $6.702 billion and total revenues were $19.154 billion; net income was $705 million, or $1.09 per share, after net investment losses of $428 million and net derivative losses of $772 million[2]. Adjusted earnings rose 15% to $1.573 billion and adjusted ROE climbed from 14.6% to 17.0%; the direct expense ratio was 12.1%, up from 11.7%, and management said it absorbed roughly 50 basis points of impact from PineBridge[2][7]. Book value per share was $38.59 at the end of June and adjusted book value per share was $57.71[2].

The third quarter of 2025 is the year-over-year comparison for this report, and it contained a small amount of notable items. That quarter's adjusted earnings were $1.584 billion, or $1.566 billion excluding $18 million of net favorable notable items; adjusted EPS was $2.37, or $2.34 excluding them, and GAAP net income per share was $1.22[5]. The notable items combined an $89 million favorable effect from the actuarial assumption review and other insurance adjustments with a $71 million unfavorable tax adjustment[5].

The company returns most of its distributable capital to shareholders while keeping holding-company cash inside its target range. In the first half of 2026 it repurchased $1.477 billion of stock and paid $755 million of common dividends, while net cash from operating activities was $4.915 billion, policyholder account balances grew by a net $6.926 billion and investing activities used a net $14.326 billion[25]. Shares outstanding were 637.8 million at the end of June[13], and holding-company cash and liquid assets were $3.4 billion, within the $3-$4 billion target range[7]; on August 5 the board approved a new $3.0 billion repurchase authorization[26].

Operating Model

MetLife's revenue consists of premiums, fees and other revenues plus net investment income, and the size of the first does not equal profit. Premiums include Group Benefits' annually renewed premiums, with group life at about $2.367 billion and non-medical health at about $2.957 billion in the second quarter[6]; they also include the PRT and U.K. reinsurance premiums that RIS collects in single payments, which reached $5.775 billion for PRT in the fourth quarter of 2025 and were $510 million in the second quarter of 2026[27]; and they include life and annuity premiums and policy fees in Asia, Latin America and EMEA. Of the $6.702 billion of second-quarter net investment income, about $998 million came from unit-linked assets that mirror customer accounts, and that income is also passed through to customers as benefits[23].

Adjusted earnings equal the sum of each segment's underwriting profit, investment spread and fee income after expenses and tax, plus Corporate & Other. Of the $1.573 billion of second-quarter adjusted earnings, Group Benefits contributed $503 million, RIS $377 million, Asia $420 million, Latin America $268 million, EMEA $108 million and MIM $57 million[9], while Corporate & Other lost $160 million[7]. Group Benefits profit depends mainly on the group life mortality ratio and the non-medical health benefit ratio, RIS profit roughly equals average retained liabilities times the core spread plus VII, and Asian profit grows with general account assets, about $141.2 billion at amortized cost in the second quarter, and with investment income[28].

VII is a volatile layer on top of RIS, Asia and Corporate & Other, while buybacks amplify per-share earnings through the denominator. Private equity and real estate funds are marked to market with a one-quarter lag[7], and company-wide after-tax VII was $183 million in the second quarter, including $94 million in Asia, $43 million in RIS and $34 million in Corporate & Other, on about $18.1 billion of related assets[12]. Adjusted EPS equals adjusted earnings divided by diluted shares, and second-quarter diluted shares were 646.9 million, about 4% fewer than the 675.0 million a year earlier[5]. GAAP net income also includes investment gains and losses, derivative gains and losses and market risk benefit remeasurement, so it can diverge sharply from adjusted earnings.

Cash flows from the insurance subsidiaries to the holding companies and then to dividends and buybacks, subject to local regulation along the way. Insurance subsidiaries pay dividends to the holding companies under statutory capital rules, and liquid assets at non-U.S. holding companies come partly from dividends of non-U.S. insurance operations that are subject to local regulatory limits[24]. The company targets a two-year average ratio of free cash flow to adjusted earnings excluding notable items of 65%-75%[29], and the holding company uses that cash to pay debt interest, dividends and buybacks while keeping a $3-$4 billion liquidity buffer[7]. Consolidated cash flow, by contrast, is shaped by large PRT and funding-agreement inflows, and in the first half both the net growth in policyholder account balances and the net cash used in investing were far larger than buybacks and dividends[25].

Industry and Competitive Position

Competition in the U.S. group insurance market happens mainly at renewal, which makes it hard for the company to keep all of an underwriting improvement for long. MetLife has built a leading position in U.S. group insurance through long-standing relationships with many of the largest U.S. employers[17]; however, its 2024 annual report warned that because it and its peers underwrite many group products annually, group customers may obtain more favorable terms from competitors at renewal[30]. Management has also said that if sustained long-term mortality improvement emerges, it will adjust pricing as appropriate[7].

In retirement and Asian markets the company competes with large life insurance groups and local insurers, while demand is driven by pension assets and product innovation. Management describes MetLife as a leading player in PRT and sees about $3 trillion of U.S. defined benefit pension assets supporting lasting demand for risk transfer, although activity was lighter in the first half of 2026 after a record 2025; in Japan, management attributes sales growth to large, diversified distribution networks, first-to-market U.S. dollar and local-currency products and consistent execution[7]. In the U.S. and Japan, MetLife competes with many domestic and foreign-owned life insurers, some of which offer broader product ranges, more competitive pricing or higher claims-paying ability ratings[30].

The company's comparative advantages lie in scale, distribution reach and investment management, but current disclosures do not allow a line-by-line peer comparison. MIM's total assets under management rose $12 billion from the prior quarter to $748 billion in the second quarter, with institutional client assets up $7 billion[7]. Public disclosures lack peer-comparable data on mortality, spreads and sales, and the company does not disclose market share, so it is impossible to tell how much of the group life underwriting advantage comes from MetLife's own pricing and how much from a broad improvement in working-age mortality.

Core Debates

Is MetLife's unusually low group life mortality a new normal or a one-off?

This question determines whether the recent jump in Group Benefits profit can last. Group Benefits is the largest segment by revenue, and its adjusted earnings rose 25% to $503 million in the second quarter of 2026[9], with the increase driven mainly by better underwriting and other insurance adjustments[31]. If the improvement in working-age mortality persists, the segment can steadily earn more than originally planned; if it reflects claim volatility or prior-period adjustments, third-quarter profit will fall back and company-wide per-share earnings growth will slow with it.

The evidence shows the improvement is real, but part of it is one-off. The second-quarter group life mortality ratio was 79.0%, below 83.0% in the second quarter of 2025, 83.4% in the third quarter of 2025 and 80.1% in the first quarter of 2026[6], and the 10-Q attributes the improvement to lower claims incidence and severity in the life business[31]. Management said about 2 percentage points came from prior-period adjustments and lower-than-expected claim severity, that July data is already starting to normalize, and that full-year mortality will return closer to trend, in line with the target range[7]; on the first-quarter call, management cited COVID-related pull-forward of deaths and GLP-1 drugs among the drivers of better working-age mortality[10]. The non-medical health benefit ratio was 73.9%, inside the 70%-75% target and compared with 72.5% in the prior-year third quarter[6]; dental rate actions have worked, but morbidity experience across products was unfavorable in the first half, with disability claims elevated by paid family leave programs[31][10].

The mortality ratio flows straight to profit through the premium base, and renewal pricing determines how long the improvement can be kept. Based on about $2.367 billion of second-quarter group life premiums, each 1-point move in the ratio is worth roughly $19 million of after-tax profit per quarter, so a return from 79% to 83% would cut quarterly profit by about $76 million, roughly 17% of the $458 million that Group Benefits earned excluding notable items in the third quarter of 2025[6][32]. Group Benefits adjusted premiums excluding participating contracts were $5.054 billion in the second quarter, up 3.7%[33], and if renewal pricing starts to give back the mortality gains, it will show up first in that growth rate. The unresolved question is whether the improvement is a durable structural change or whether price cuts that customers demand at renewal will gradually absorb it.

Four signals in the third quarter will test this debate. One is whether the mortality ratio stays below 82% and whether management again cites prior-period adjustments; another is whether the non-medical health benefit ratio holds under its 75% ceiling and disability claims improve; a third is whether premium growth excluding participating contracts stays above 3.5% without signs of renewal price cuts; and the last is whether Group Benefits earnings excluding notable items beat the $458 million of a year earlier[32]. If the ratio returns above 83% or the benefit ratio exceeds 75%, the "new normal" reading is falsified and the second-quarter profit level should be treated as an unusually high single quarter.

Can core spread and liability growth put MetLife's retirement business back on track for its full-year earnings guidance?

RIS is the segment that tests MetLife's spread-based earnings, and the third quarter will directly test its full-year guidance. RIS contributed $1.671 billion of adjusted earnings in 2025[16], and its profit roughly equals retained liabilities times the spread plus VII; second-quarter earnings grew only 2%[9], mainly because VII fell sharply[19]. Management has kept full-year guidance of $1.6-$1.8 billion[10], the first half delivered $828 million[27], and the second half therefore needs roughly $386-$486 million a quarter, which makes the third quarter the key check on the guidance.

The core spread has stabilized and recovered, but the total spread and liability growth both sit at the low end of expectations. The second-quarter core spread excluding VII was 1.00%, up from 0.95% in the first quarter, but the total spread including VII was only 0.97% because the VII yield was just 4.13%, compared with 13.46% in the third quarter of 2025[8]; management acknowledged that the total spread was below its 100-120 basis point full-year expectation[7]. The 10-Q attributes lower VII to weaker returns on private equity funds and mortgage loan funds[19]. Adjusted premiums excluding PRT rose 19% to $1.259 billion[33], driven mainly by U.K. longevity reinsurance and structured settlements; PRT premiums declined, but U.K. funded reinsurance has topped $1 billion so far this year, and retained liabilities grew 3%, at the low end of the 3%-5% target[7].

RIS profit is built from three stacked layers: new liability volume, the core spread and VII with a one-quarter lag. New liabilities from PRT, structured settlements, U.K. longevity reinsurance and funded reinsurance, net of the portion ceded to Chariot Re, form average retained liabilities[22], which multiplied by the core spread between fixed-income and mortgage yields and crediting costs produce RIS recurring earnings, while private equity and real estate fund returns enter VII with a one-quarter lag. Management guided the core spread to stay within 95-100 basis points in the second half[7], and in the first quarter it flagged the flat yield curve as a headwind for spreads[10]. One reading holds that the profit dip is mainly a VII timing issue and the core business is stable; another holds that if the curve stays flat and reinvestment yields fall, the core spread will come under pressure and a VII rebound alone will not support the full-year guidance.

Three signals in the third quarter will test this debate. One is whether the core spread stays above 0.95%, ideally no lower than the 0.98% of a year earlier[8]; another is whether RIS earnings beat the $386 million per quarter needed to hold the bottom of guidance, compared with $428 million excluding notable items and $1.224 billion of premiums excluding PRT a year earlier[27], and whether the company keeps its $1.6-$1.8 billion guidance; the last is how management describes retained liability growth and the fourth-quarter PRT deal pipeline. If the core spread falls below 0.95% or retained liability growth drops under 3%, the reading that the profit dip is "just timing" will weaken.

Can sales growth in Japan and Korea keep turning into assets and earnings for MetLife Asia?

Asian sales growth is one of MetLife's main sources of medium-term earnings growth, but it has to build assets before it becomes profit. Asia is the company's highest-earning segment, with $1.702 billion of adjusted earnings in 2025[16]. Japanese customers buy foreign-currency annuities and yen life insurance whose funds flow into the general account as investable assets, while Korea is mainly about life premiums[20]; sales growth shows up first in asset size and then turns into profit quarter by quarter.

Sales and assets both grew in the second quarter, but earnings face a high year-over-year base. Asian constant-currency sales were $794 million in the second quarter, up 17%; Japan contributed $457 million, up about 2%, with medical sales rising from $62 million to $118 million, and Other Asia contributed $337 million, up about 45%[28]. Constant-currency general account assets at amortized cost grew 5.8% to $141.2 billion[28], and the 10-Q also notes higher fee income from Japan's foreign-currency annuity and yen life products[20]. Asian adjusted earnings were $420 million, up 21%[9]; however, third-quarter 2025 earnings were $540 million, including $70 million of favorable notable items, or $470 million excluding them and $450 million at constant currency[28].

The Asian earnings chain starts with new business and runs through asset accumulation, while VII and currency add noise. New foreign-currency and yen products and medical cover in Japan, plus Korean life policies, generate constant-currency sales that settle into general account assets and reach Asian adjusted earnings through investment spread and insurance margins; Asia holds about $8.6 billion of VII-related assets, which produced $94 million of after-tax VII in the second quarter[12] versus $183 million in the first[11], and the yen exchange rate also affects reported results. An alternative reading is that a considerable part of Asian earnings growth comes from VII and reinvestment at higher rates rather than from new business itself; in addition, management mentioned an industry-wide inquiry by Japanese regulators in the first quarter, while saying it had no impact on the business or sales[10].

Three signals in the third quarter will test this debate. One is whether Asian constant-currency sales exceed the $769 million of a year earlier and whether Japan holds $451 million[28]; another is whether general account assets keep growing at more than 5% a year; the last is whether Asian earnings excluding notable items are at least $450 million, and how much of that comes from VII. If Japanese sales decline, asset growth drops below 5% or earnings growth relies mainly on VII, the view that sales keep converting into earnings will need revising.

After a weak quarter for alternative investment income, can MetLife's per-share earnings reach the roughly $2.77 the market expects?

Third-quarter EPS expectations require several conditions to hold at once, which makes this the most direct company-wide test. The $2.77 consensus is about 17% above the $2.37 reported a year earlier[4][5], and it needs a VII recovery, continued good underwriting and ongoing buybacks to happen together. VII comes from private equity and real estate funds that are marked to market with a one-quarter lag and swing widely from quarter to quarter[7]; at the same time, the company buys back billions of dollars of stock each year, steadily shrinking the share count.

Second-quarter EPS growth came mainly from underwriting, while VII was a drag. The 2025 annual report assumed a 9% private equity return in 2026, contributing about $1.6 billion of pre-tax VII for the full year[29]; after-tax VII was $409 million in the first quarter and fell to $183 million in the second, for $592 million in the first half[11][12]. Second-quarter adjusted EPS was $2.43, up 20%, driven by favorable underwriting and volume growth[9]. The company repurchased $1.477 billion of stock in the first half[25], shares outstanding fell from 666.8 million a year earlier to 637.8 million[13], and a new $3.0 billion repurchase authorization was added in August[26].

Per-share earnings move through three channels: VII, buybacks and the actuarial review. Changes in the market value of private equity and real estate funds enter after-tax VII with a one-quarter lag and then flow into adjusted earnings; subsidiary dividends replenish holding-company cash, and buybacks reduce diluted shares and raise EPS. Using 646.9 million diluted shares from the second quarter, each $100 million shortfall in after-tax VII against roughly $300 million per quarter lowers EPS by about $0.15, or about 5% of the $2.77 consensus[5]. The third quarter is also when the annual actuarial assumption review takes place; in the third quarter of 2025, the review and other insurance adjustments produced an $89 million favorable effect, which combined with tax adjustments to give $18 million of net favorable notable items[5], leaving the measure excluding notable items unaffected but changing reported results. An alternative reading is that much of the second quarter's strong growth came from one-off mortality favorability, so if underwriting returns to trend in the second half, EPS may struggle to reach the market's expectation even if VII recovers.

Four signals in the third quarter will test this debate. One is whether after-tax VII returns to around $300 million and whether management keeps its full-year private equity return assumption; another is whether adjusted EPS excluding notable items reaches $2.77, or at least grows 10% from the prior-year $2.34 to about $2.58[5]; a third is the direction and size of notable items from the actuarial review; and the last is whether the quarter-end share count and holding-company cash support the buyback pace. If VII stays below $300 million while the actuarial review produces a large unfavorable item, the case for sustained double-digit per-share earnings growth will weaken.

Risks and Falsifiers

A deterioration in commercial mortgage and private credit quality would weaken the company's buyback capacity through capital. The general account holds a large commercial mortgage book, mortgage loans produced $1.097 billion of investment income in the second quarter[23], the company sets credit loss allowances for most commercial and agricultural mortgage loans using a two-year economic forecast plus historical default experience[34], and in the first quarter management said it was cautious on commercial mortgages and was reallocating toward asset-backed finance and other private assets[10]. Credit losses go through GAAP investment gains and losses rather than adjusted earnings, but they reduce book value and statutory capital and therefore subsidiary dividends and buybacks, while lower income from defaults would erode spreads in RIS and Asia. If third-quarter mortgage credit loss allowances and delinquencies do not rise noticeably, holding-company cash stays above $3 billion and buybacks continue, this risk has not materialized.

The third-quarter annual actuarial assumption review could produce large unfavorable notable items, with run-off businesses such as long-term care as the main exposure. Those run-off businesses sit in Corporate & Other[15]; notable items do not affect earnings excluding notable items, but they directly change reported adjusted earnings and book value per share. In the third quarter of 2025 the segments moved in different directions: Asia had a favorable $70 million[28], RIS a favorable $13 million[27] and Group Benefits an unfavorable $2 million[32]. If total third-quarter notable items are below $100 million in absolute value and run-off businesses have no unfavorable reserve adjustment, this risk is falsified.

Second-quarter low mortality may have come mainly from prior-period claim adjustments and unusually low severity, and the ratio could return to the 83%-88% target range in the third quarter[7]. Each 1-point rise in the ratio lowers Group Benefits after-tax profit by about $19 million a quarter, and a return from 79% to 83% would cost about $76 million[6]. If the third-quarter mortality ratio is no higher than 82% and management does not attribute the improvement to prior-period adjustments, this risk is falsified.

If the core spread falls below 0.95% and VII does not rebound, full-year RIS earnings could miss the $1.6 billion bottom of guidance[10]. RIS earned $828 million in the first half and needs at least $772 million in the second; if the third and fourth quarters both repeat the second quarter's $377 million, the full year would come to about $1.582 billion, roughly $18 million short of the guidance floor[27]. If third-quarter RIS earnings are at least $428 million and the core spread is no lower than 0.98%, this risk is falsified[8].

Sales of Japanese foreign-currency products could fall because of currency or interest-rate swings or the industry regulatory inquiry, slowing Asian asset growth[10]. Japan made up about 58% of second-quarter Asian sales ($457 million of $794 million)[28], and a sales decline would slow general account asset growth over the following quarters and weaken the growth base for Asia's roughly $1.7 billion of annual earnings[16]. If third-quarter Japanese sales are flat or up year over year and Asian general account assets grow at least 5%, this risk is falsified.

Private equity and real estate fund returns could stay below the 9% assumed in the 2025 annual report, keeping VII weak[29]. Each $100 million shortfall in quarterly after-tax VII against about $300 million lowers EPS by about $0.15 on 646.9 million diluted shares[5], about 5% of the $2.77 consensus[4], and it would weigh on RIS, Asia and Corporate & Other at the same time. If third-quarter after-tax VII is at least $300 million, this risk is falsified.

What to Watch Next

• Group life mortality: whether the mortality ratio (79.0% in the second quarter of 2026, 83.4% a year earlier) stays below 82%; a return above 83% falsifies the durable-improvement view.
• Group Benefits health and pricing: whether the non-medical health benefit ratio (73.9%) holds under 75% and premium growth excluding participating contracts ($5.054 billion, up 3.7%) stays above 3.5%.
• RIS spread: whether the core spread excluding VII (1.00% in the second quarter, 0.98% a year earlier) stays above 0.95%.
• RIS earnings and guidance: whether quarterly earnings beat $386 million against $428 million a year earlier, and whether the $1.6-$1.8 billion guidance is kept.
• Asia conversion: whether constant-currency sales top $769 million with Japan at $451 million or more, whether general account assets keep growing above 5%, and whether earnings excluding notable items reach $450 million without leaning on VII.
• VII and EPS: whether after-tax VII returns to about $300 million, whether adjusted EPS excluding notable items reaches $2.77 or at least about $2.58, and whether the actuarial review produces a large unfavorable notable item.

Conclusion

MetLife's earnings run on three engines: Group Benefits underwriting, RIS liability volume times spread, and the general account assets that Asian sales build up, with VII and buybacks amplifying or eroding per-share earnings on top. In the second quarter of 2026, adjusted EPS rose 20% to $2.43 and adjusted ROE was 17.0%[2], while holding-company cash of $3.4 billion stayed within the $3-$4 billion target range[7]. The central unresolved relationship is that the 79.0% group life mortality ratio[6] and the low $183 million of VII[12] pulled in opposite directions in the second quarter, both may revert toward normal in the third, and whether EPS reaches $2.77 depends on whether a VII recovery and a lower share count can offset any underwriting pullback.

Since second-quarter results were released on August 5, 2026, the outside commentary available publicly has consisted only of brokers adjusting their views on the share price and a report that Michael Burry took a short position in MetLife through long-dated put options in late September, and neither offered a verifiable operating argument. Independent analysis of group life mortality, RIS spreads or the third-quarter report itself is also missing, so this piece treats no outside view as support for any of the four debates above; for now, the market's expectation for this report can be read only from the $2.77 EPS figure compiled from 12 analysts[4].

If the third-quarter group life mortality ratio is no higher than 82%, the RIS core spread is no lower than 0.98% with earnings of at least $428 million, after-tax VII returns to about $300 million, Asian general account assets keep growing above 5% and the actuarial review brings no large unfavorable item, the current view that earnings growth is durable would strengthen materially. Conversely, if the mortality ratio returns above 83%, the core spread falls below 0.95%, VII stays below $300 million, or holding-company cash drops below $3 billion while buybacks slow, the second-quarter profit level would look more like a single quarter in which several favorable factors happened to line up.

Sources

[1] Drillr earnings calendar MET updated 2026-10-30 · 2026-10-30 · Drillr earnings calendar · https://gateway.drillr.ai/mcp/private

[2] MET Q2 2026 8-K financial highlights table · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[3] MET FY2025 10-K consolidated outlook · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[4] Drillr analyst estimates MET Q3 2026 retrieved 2026-10-30 · 2026-10-30 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[5] MET Q2 2026 8-K corporate overview by quarter · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[6] MET Q2 2026 8-K Group Benefits supplement · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[7] MET Q2 2026 earnings call 2026-08-06 · 2026-08-06 · earnings-call · https://gateway.drillr.ai/mcp/private

[8] MET Q2 2026 8-K RIS spread supplement · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[9] MET Q2 2026 8-K filed 2026-08-05 · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[10] MET Q1 2026 earnings call 2026-05-07 · 2026-05-07 · earnings-call · https://gateway.drillr.ai/mcp/private

[11] MET Q1 2026 8-K filed 2026-05-06 · 2026-05-06 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[12] MET Q2 2026 8-K variable investment income by segment · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[13] MET Q2 2026 8-K share count and ROE by quarter · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[14] MET FY2025 10-K filed 2026-02-19 · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[15] MET FY2025 10-K Corporate & Other run-off businesses · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[16] MET FY2025 10-K segment adjusted earnings · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[17] MET FY2025 10-K Group Benefits business · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[18] MET Q2 2026 10-Q RIS revenue overview · 2026-08-06 · 10-Q · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000050/

[19] MET Q2 2026 10-Q RIS discussion · 2026-08-06 · 10-Q · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000050/

[20] MET Q2 2026 10-Q Asia revenue overview · 2026-08-06 · 10-Q · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000050/

[21] MET FY2025 10-K PineBridge acquisition · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[22] MET FY2025 10-K Chariot Re reinsurance · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[23] MET Q2 2026 10-Q net investment income composition · 2026-08-06 · 10-Q · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000050/

[24] MET FY2025 10-K holding company liquid assets · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[25] MET Q2 2026 10-Q liquidity sources and uses · 2026-08-06 · 10-Q · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000050/

[26] MET 8-K filed 2026-08-05 new repurchase authorization · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[27] MET Q2 2026 8-K RIS adjusted earnings by quarter · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[28] MET Q2 2026 8-K Asia supplement · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[29] MET FY2025 10-K variable investment income assumption · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/

[30] MET FY2024 10-K competition (prior annual filing) · 2025-02-21 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=10-K

[31] MET Q2 2026 10-Q Group Benefits discussion · 2026-08-06 · 10-Q · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000050/

[32] MET Q2 2026 8-K Group Benefits adjusted earnings by quarter · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[33] MET Q2 2026 8-K segment reconciliation excluding participating contracts and PRT · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001099219&type=8-K&dateb=&owner=include&count=40

[34] MET FY2025 10-K commercial mortgage loan allowance methodology · 2026-02-19 · 10-K · https://www.sec.gov/Archives/edgar/data/1099219/000109921926000013/